liquidNodule: Pulmonary Nodule Cohort
Sponsor
Seoul National University Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04049422
Collaborator
(none)
1,000
119.8
Study Details
Study Description
Brief Summary
The aim of this study is to identify the clinical features of pulmonary nodules and establish a cohort to identify biomarkers for lung cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Study Type:
Observational [Patient Registry]
Anticipated Enrollment
:
1000 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Pulmonary Nodule Cohort
Anticipated Study Start Date
:
Aug 6, 2019
Anticipated Primary Completion Date
:
Jul 31, 2024
Anticipated Study Completion Date
:
Jul 31, 2029
Outcome Measures
Primary Outcome Measures
- Incidence of lung cancer [up to 5 years]
incidence of pathologically proven lung cancer
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
age >= 18
-
pulmonary nodule(s) on chest CT, which satisfy at least one of the following two criteria,
-
4A or above in Lung-RADS v1.1
-
lung cancer risk >= 5% in Brock model
Exclusion Criteria:
- already proven lung cancer
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Seoul National University Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Young Sik Park,
Associate Professor,
Seoul National University Hospital
ClinicalTrials.gov Identifier:
NCT04049422
Other Study ID Numbers:
- 1907-099-1048
First Posted:
Aug 8, 2019
Last Update Posted:
Aug 8, 2019
Last Verified:
Aug 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: